SLU researchers uncover direct evidence on how HIV invades healthy cells

December 21, 2005

Using sophisticated detection methods, researchers at the Saint Louis University Institute for Molecular Virology (IMV) have demonstrated the molecular mechanism by which the HIV virus infects, or integrates, healthy cells. The discovery could lead to new drug treatments for HIV.

Although scientists theorized that two ends of the virus' DNA must come together inside a healthy cell in order to infect it, until now, investigators have not been able to illuminate the process.

"Many biological and structural aspects of HIV integration are undefined," said Sibes Bera, Ph.D. "Therefore, any insight into the molecular mechanism of this process is significant in developing integrase inhibitors."

Integrase, which was discovered by SLU researchers in 1978, is one of three HIV proteins crucial to the infection's survival. The first protein, reverse transcriptase, converts the ribonucleic acid (RNA) in HIV into deoxyribonucleic acid (DNA).

Integrase then inserts the HIV DNA into the immune cell's DNA, making it a permanent part of the cell. The third protein, protease, processes viral proteins and is essential to make infectious virus.

Drugs such as AZT and drug combinations (cocktails) exist to inhibit reverse transcriptase and protease. As of yet, there are no drugs to counter integrase.

By using a biophysical methodology known as Fluorescence Resonance Energy Transfer, Bera and his colleagues showed that the integrase holds the two ends of the viral DNA together prior to integration. Once inside the cell, the two viral DNA ends are fused by the integrase to the cell's chromosome. The integrated viral DNA allows virus replication. If the two ends of the viral DNA do not come together, infection does not take place. Millions of HIV tainted cells can be launched from a single infected cell.

"We will use this technique in our ongoing studies of the effects of drugs in the process of assembly and disassembly of the viral DNA integrase complexes," Bera said.
-end-
The findings were published in the journal Biochemistry. The study is entitled, "Synaptic Complex Formation of Two Retrovirus DNA Attachment Sites by Integrase: A Fluorescence Energy Transfer Study" by Bera and his colleagues, Ajaykumar C. Vora, M.S., Roger Chiu and Duane P. Grandgenett, Ph.D., from Institute for Molecular Virology and Tomasz Heyduk, Ph.D., from department of biochemistry and molecular biology. The paper was categorized in the journal as a "hot article," a status reserved for findings of a significant nature.

Link: http://pubs3.acs.org/acs/journals/hot_article.menu?in_coden=bichaw

Editor's Note: For further information or to arrange an interview with Dr. Bera or one of his colleagues, contact Joe Muehlenkamp at Saint Louis University, (314) 977-8015.

Saint Louis University

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.